Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 309

[108] Robinson LA, Smith LJ, Fontaine MP, Kay HD, Mountjoy CP, Pirruccello SJ. C-myc
antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
Ann Thorac Surg 1995;60:1583-91.
[109] Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras
expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res
1991;51:1744-8.
[110] Cochet O, Kenigsberg M, Delumeau I, Virone Oddos A, Multon MC, Fridman WH,
et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes
tumor regression. Cancer Res 1998;58:1170-6.
[111] Tanner NK. Ribozymes: the characteristics and properties of catalytic RNAs. FEMS
Microbiol Rev 1999;23:257-75.
[112] Zhang Y, Nemunaitis J, Scanlon KJ, Tong AW. Anti-tumorigenic effect of a K-ras ribo-
zyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther
2000;7:2041-50.
[113] Vincent RG, Chu TM, Lane WW, Gutierrez AC, Stegemann PJ, Madajewicz S.
Carcinoembryonic antigen as a monitor of successful surgical resection in 130 patients
with carcinoma of the lung. J Thorac Cardiovasc Surg 1978;75:734-9.
[114] Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and
immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus
vaccine. J Natl Cancer Inst 1992;84:1084-91.
[115] Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, et al. Immunogenicity and
safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen
gene in a nonhuman primate. Cancer Res 1992;52:6917-25.
[116] Cole DJ, Wilson MC, Baron PL, O'Brien P, Reed C, Tsang KY, et al. Phase I study of
recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge.
Hum Gene Ther 1996;7:1381-94.
[117] Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, et al.
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in
patients with small cell lung cancer. Clin Cancer Res 1999;5:2773-9.
[118] Lee L, Wang RF, Wang X, Mixon A, Johnson BE, Rosenberg SA, et al. NY-ESO-1 may
be a potential target for lung cancer immunotherapy. Cancer J Sci Am 1999;5:20-5.
[119] Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance
and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res
1998;58:315-21.
[120] Pardoll DM. Genetically engineered tumor vaccines. Ann NY Acad Sci 1993;690:301-10.
[121] You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy
in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
Cancer Res 2000;60:1009-13.
[122] Huynh HG, Deen DF, Szoka Jr FC. Barriers to carrier mediated drug and gene delivery
to brain tumors. J Contr Release 2006;110:236-59.
[123] Chen SJ, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain
tumors: regression of experimental gliomas by adenovirus- mediated gene transfer in
vivo . Proc Natl Acad Sci USA 1994;91:3054-7.
[124] Culver K, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer
with retroviral vector-producer cells for treatment of experimental brain tumors. Science
1992;256:1550-2.
[125] Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL,
et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is
genetically modified. Cancer Res 1993;53:5274-83.